X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN LTD CADILA HEALTHCARE/
LUPIN LTD
 
P/E (TTM) x 32.8 22.8 144.0% View Chart
P/BV x 6.5 3.1 210.5% View Chart
Dividend Yield % 0.7 0.8 89.2%  

Financials

 CADILA HEALTHCARE   LUPIN LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
LUPIN LTD
Mar-17
CADILA HEALTHCARE/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4601,750 26.3%   
Low Rs3051,384 22.0%   
Sales per share (Unadj.) Rs92.1387.4 23.8%  
Earnings per share (Unadj.) Rs14.856.6 26.2%  
Cash flow per share (Unadj.) Rs18.576.8 24.1%  
Dividends per share (Unadj.) Rs3.207.50 42.7%  
Dividend yield (eoy) %0.80.5 174.8%  
Book value per share (Unadj.) Rs68.0298.9 22.7%  
Shares outstanding (eoy) m1,023.74451.58 226.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.24.0 102.7%   
Avg P/E ratio x25.827.7 93.3%  
P/CF ratio (eoy) x20.720.4 101.5%  
Price / Book Value ratio x5.65.2 107.3%  
Dividend payout %21.613.2 163.1%   
Avg Mkt Cap Rs m391,581707,513 55.3%   
No. of employees `00016.916.8 100.4%   
Total wages/salary Rs m15,00228,495 52.6%   
Avg. sales/employee Rs Th5,594.510,418.3 53.7%   
Avg. wages/employee Rs Th890.11,697.0 52.5%   
Avg. net profit/employee Rs Th899.91,523.0 59.1%   
INCOME DATA
Net Sales Rs m94,295174,943 53.9%  
Other income Rs m1,2861,065 120.7%   
Total revenues Rs m95,581176,008 54.3%   
Gross profit Rs m19,03644,931 42.4%  
Depreciation Rs m3,7509,122 41.1%   
Interest Rs m4501,525 29.5%   
Profit before tax Rs m16,12235,349 45.6%   
Minority Interest Rs m338-72 -471.4%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2899,785 13.2%   
Profit after tax Rs m15,16825,575 59.3%  
Gross profit margin %20.225.7 78.6%  
Effective tax rate %8.027.7 28.9%   
Net profit margin %16.114.6 110.0%  
BALANCE SHEET DATA
Current assets Rs m60,223119,542 50.4%   
Current liabilities Rs m53,05861,206 86.7%   
Net working cap to sales %7.633.3 22.8%  
Current ratio x1.12.0 58.1%  
Inventory Days Days7076 91.9%  
Debtors Days Days8890 98.1%  
Net fixed assets Rs m72,984131,660 55.4%   
Share capital Rs m1,024903 113.4%   
"Free" reserves Rs m68,576134,073 51.1%   
Net worth Rs m69,600134,976 51.6%   
Long term debt Rs m24,68456,478 43.7%   
Total assets Rs m152,207266,073 57.2%  
Interest coverage x36.824.2 152.3%   
Debt to equity ratio x0.40.4 84.8%  
Sales to assets ratio x0.60.7 94.2%   
Return on assets %10.310.2 100.7%  
Return on equity %21.818.9 115.0%  
Return on capital %17.919.3 93.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28081,885 26.0%   
Fx outflow Rs m10,87421,506 50.6%   
Net fx Rs m10,40660,378 17.2%   
CASH FLOW
From Operations Rs m13,49541,148 32.8%  
From Investments Rs m-29,103-25,287 115.1%  
From Financial Activity Rs m23,1584,332 534.6%  
Net Cashflow Rs m7,55620,193 37.4%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 19, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS